Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Tactics used x Hedge Fund & MM to acquire shareholder stock

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Dec 23, 2022 11:30am

127 Views

Post# 35189542

RE:RE:RE:RE:RE:RE:Tactics used x Hedge Fund & MM to acquire shareholder stock

And as one sees their trading the stock comes with a plethora of "trumped-up" posts that consist of lies, falsehoods, distractions and distortions that are full of denials and false assertions in an attempt to hide their motives for being here.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec